• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.继发于SGLT2抑制剂治疗的长期酮症和糖尿
Clin Case Rep. 2021 Nov 9;9(11):e05057. doi: 10.1002/ccr3.5057. eCollection 2021 Nov.
2
SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report.钠-葡萄糖协同转运蛋白2抑制剂所致正常血糖性糖尿病酮症酸中毒：一例报告
Kidney Med. 2020 Feb 22;2(2):218-221. doi: 10.1016/j.xkme.2019.12.006. eCollection 2020 Mar-Apr.
3
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.与钠-葡萄糖协同转运蛋白2抑制剂卡格列净相关的伴有长期糖尿的正常血糖性糖尿病酮症酸中毒
J Investig Med High Impact Case Rep. 2017 Jun 8;5(2):2324709617712736. doi: 10.1177/2324709617712736. eCollection 2017 Apr-Jun.
4
A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old.一例28岁经皮冠状动脉介入治疗（PCI）后因钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂诱发正常血糖性糖尿病酮症酸中毒而长期恢复的病例
Cureus. 2023 Sep 13;15(9):e45180. doi: 10.7759/cureus.45180. eCollection 2023 Sep.
5
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.SGLT2抑制剂相关的酮症及糖尿病酮症酸中毒：基本机制与治疗前景
Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23.
6
A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂诱发正常血糖性糖尿病酮症酸中毒治疗前景的文献综述
Cureus. 2022 Sep 27;14(9):e29652. doi: 10.7759/cureus.29652. eCollection 2022 Sep.
7
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒：一例病例报告及文献综述
Int J Emerg Med. 2019 Sep 5;12(1):27. doi: 10.1186/s12245-019-0240-0.
8
Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.达格列净继发正常血糖性糖尿病酮症酸中毒患者的长期酮症状态
J Investig Med High Impact Case Rep. 2017 May 24;5(2):2324709617710040. doi: 10.1177/2324709617710040. eCollection 2017 Apr-Jun.
9
Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.肾小管损伤导致钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂停药后长期糖尿：在迁延性低血糖和酮症酸中毒发展中的可能作用。
Tohoku J Exp Med. 2021 Dec;255(4):291-296. doi: 10.1620/tjem.255.291.
10
Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report.与 SGLT2 抑制剂治疗相关的血糖正常的糖尿病酮症酸中毒：病例报告。
AACN Adv Crit Care. 2023 Mar 15;34(1):27-32. doi: 10.4037/aacnacc2023830.

引用本文的文献

1
Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂治疗的患者因脓毒症引发的正常血糖性糖尿病酮症酸中毒：一例诊断和治疗挑战的病例
Cureus. 2025 Jun 30;17(6):e87029. doi: 10.7759/cureus.87029. eCollection 2025 Jun.
2
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes.新视野：钠-葡萄糖协同转运蛋白2抑制剂在糖尿病之外的临床应用及多方面益处
Front Cardiovasc Med. 2025 Mar 20;12:1482918. doi: 10.3389/fcvm.2025.1482918. eCollection 2025.
3
Euglycemic Ketoacidosis in a Patient without Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure.心力衰竭患者服用钠-葡萄糖共转运蛋白 2 抑制剂后出现血糖正常性酮症酸中毒。
Am J Case Rep. 2024 Jul 10;25:e943945. doi: 10.12659/AJCR.943945.
4
ERRATUM.勘误
Clin Case Rep. 2021 Nov 25;9(11):e05137. doi: 10.1002/ccr3.5137. eCollection 2021 Nov.

本文引用的文献

1
SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.在一个多中心队列中，SGLT-2 抑制剂与血糖正常和高血糖性 DKA 相关。
Sci Rep. 2021 May 13;11(1):10293. doi: 10.1038/s41598-021-89752-w.
2
Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.由SGLT2抑制剂和生酮饮食引起的正常血糖性糖尿病酮症酸中毒：病例系列及文献综述
AACE Clin Case Rep. 2020 Dec 28;7(1):17-19. doi: 10.1016/j.aace.2020.11.009. eCollection 2021 Jan-Feb.
3
15. Diabetes Care in the Hospital: .医院中的糖尿病护理： 。
Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220. doi: 10.2337/dc21-S015.
4
Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor.单次服用钠-葡萄糖共转运蛋白 2 抑制剂引发的长时间血糖正常性糖尿病酮症酸中毒。
BMJ Case Rep. 2020 Oct 7;13(10):e235969. doi: 10.1136/bcr-2020-235969.
5
Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy.与SGLT2抑制剂治疗相关的持续性糖尿和糖尿病酮症酸中毒复发。
Endocrinol Diabetes Metab. 2020 Feb 29;3(2):e00117. doi: 10.1002/edm2.117. eCollection 2020 Apr.
6
Sodium-Glucose Cotransporter 2 Inhibitor-Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review.2型糖尿病中钠-葡萄糖协同转运蛋白2抑制剂相关的持续性血糖正常的糖尿病酮症酸中毒：一例报告及文献综述
Clin Diabetes. 2020 Jan;38(1):112-116. doi: 10.2337/cd19-0035.
7
Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.卡格列净所致正常血糖性糖尿病酮症酸中毒：一例报告
Int J Emerg Med. 2020 Jan 22;13(1):2. doi: 10.1186/s12245-020-0261-8.
8
Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis.长期酸中毒是SGLT2抑制剂诱发的正常血糖性糖尿病酮症酸中毒的一个特征。
Endocrinol Diabetes Metab Case Rep. 2019 Sep 27;2019. doi: 10.1530/EDM-19-0087.
9
Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.使用和未使用 SGLT2 抑制剂的糖尿病酮症酸中毒患者的临床特征。
Diabetes Metab. 2019 Oct;45(5):453-457. doi: 10.1016/j.diabet.2019.01.001. Epub 2019 Jan 9.
10
Prolonged diabetic ketoacidosis associated with canagliflozin.与卡格列净相关的延长的糖尿病酮症酸中毒
Endocrinol Diabetes Metab Case Rep. 2018 Jun 6;2018. doi: 10.1530/EDM-17-0177. eCollection 2018.

继发于SGLT2抑制剂治疗的长期酮症和糖尿

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.

作者信息

Bobrowski David, Kumar Reha, Wu Peter E, Lapointe-Shaw Lauren

机构信息

Department of Medicine University of Toronto Toronto Ontario Canada.

Division of Clinical Pharmacology & Toxicology University of Toronto Toronto Ontario Canada.

出版信息

Clin Case Rep. 2021 Nov 9;9(11):e05057. doi: 10.1002/ccr3.5057. eCollection 2021 Nov.

DOI:10.1002/ccr3.5057
PMID:34786197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8577244/
Abstract

Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half-lives, the typical duration used to guide pre-operative medication recommendations.

摘要

临床医生应意识到，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的药理活性可能在五个半衰期的标准药物清除期（用于指导术前用药建议的典型时长）之后仍持续很长时间。